Miami Biotech Longeveron Will Attend October Conferences
The Miami-based company heads to three events this October to discuss its investigational Alzheimer’s treatment.
Updated on Sept. 30, 2026 in Alzheimer’s
Live Poll
Is now a good time for individual investors to support emerging longevity-focused biotech companies?
Miami-based Longeveron will participate in three upcoming investment and longevity conferences this October. The company recently published preprint findings on its investigational Alzheimer’s treatment, laromestrocel.
Why it matters
As the company seeks further funding and research partnerships, these industry meetings offer a platform to advance development of its potential therapy. Longeveron aims to protect brain tissue and function for those suffering from Alzheimer’s disease.
Longeveron recently secured a $1,000,000 Milestone 2 Award from the XPRIZE Healthspan competition, which drew 600 initial applicants. The firm is now competing for a potential grand prize of up to $81 million.
The players
Longeveron
A Miami-based biotechnology company developing regenerative medicine therapies.
The details
Longeveron will present findings during meetings in Boston and South San Francisco, as well as the Abundance Longevity Trip. Its investigational product, laromestrocel, is derived from donor bone marrow stem cells and is currently undergoing analysis to determine its impact on neuroinflammation. These sessions follow the publication of a recent preprint manuscript on medRxiv detailing Phase 2a data.
Timeline
October 1-3, 2026: Aging Research and Drug Discovery Meeting in Boston.
October 7-11, 2026: Abundance Longevity Trip.
October 19-20, 2026: Longevity Partnering Forum in South San Francisco.
Beyond the 305
Longeveron is currently among the finalists in the global XPRIZE Healthspan competition, which seeks to reward breakthroughs in extending human health. This status marks a significant step forward from the company's previous clinical-stage research and development milestones.
Local residents and investors should watch for potential shifts in the company's funding status as it moves toward its next phase of trials. These upcoming conferences serve as key milestones for the firm's progress in Alzheimer's research.
The takeaway
Longeveron is leveraging its current clinical data to gain visibility on the national biotech stage. Residents can follow the company's progress as it advances toward potential Grand Prize consideration in the XPRIZE competition.
Further reading
Learn more about local research and support resources in our Alzheimer’s section.
More information
Review the full preprint manuscript regarding the phase 2a clinical trial data.
Live Poll
Is now a good time for individual investors to support emerging longevity-focused biotech companies?
